

Gout: Diagnosis and Management Committee meeting 3

Date: 30/10/2020

Location: Video-conference via Zoom

Minutes: Final

Committee members present:		
Aung Soe		(Present for notes 1 – 4)
Ed Roddy		(Present for notes 1 – 4)
Alastair Dickson		(Present for notes 1 – 4)
Sam Finnikin		(Present for notes 1 – 4)
Kelsey Jordan		(Present for notes 1 – 4)
Mohammed Ifaniq		(Present for notes 1 – 4)
Jane Taylor		(Present for notes 1 – 4)
Sarah Ryan		(Present for notes 1 – 4)

In attendance:		
Clifford Middleton	Guideline Commissioning Manager, NICE	(Present for notes 1 – 4)
Brett Doble	Health Economic Lead, NICE	(Present for notes 1)
Amber Hernaman	Project Manager, NGC	(Present for notes 1 – 4)
Sedina Lewis	Senior Research Fellow, NGC	(Present for notes 1 – 4)
Joseph Runicles	Information Specialist, NGC	(Present for notes 1 – 4)
Gill Ritchie	Guideline Lead, NGC	(Present for notes 1 – 4)
Audrius Stonkus	Research Fellow, NGC	(Present for notes 1 – 4)
Alexandra Bonnon	Health Economist, NGC	(Present for notes 1 – 4)

Apologies:	
Ben Williams-Shaw	Lay member
Hugh Gallagher	Committee member

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the third guideline committee meeting on gout.

Brett Doble, Health Economic Lead introduced himself to the committee

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was

- pharmacological prevention of flares evidence review
- 4.3+4.4 ULT second-line treatment
- 5.1 Treat to target
- 5.4 Follow up after flares

The Chair asked everyone to verbally declare any interests. There were no new declarations

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Presentations, questions and discussion

- a) Audrius Stonkus presented on minimum important difference
- b) Sedina Lewis presented and led the discussion on the pharmacological prevention of flares evidence review and the committee drafted the initial recommendations
- c) The committee discussed and agreed the draft protocol for question:
 - 4.3+4.4 ULT second-line treatment
 - 5.1 Treat to target

- 5.4 Follow up after flares

d) Alexandra Bonnon presented and led the discussion on the health economic plan

4. Any other business

The committee were updated that Ben Williams-Shaw was no longer able to contribute to the work of the guideline committee and was therefore stepping down from the committee. The committee were asked to let Amber Hernaman know if they were aware of anyone who might be interested in joining the committee as a lay member.

Date of next meeting: 04/12/20

Location of next meeting: Video-conference